Brain tumor scientists map mutation that drives tumors in childhood cancer survivors

August 4, 2017

Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumour, decades after their treatment with cranial radiation.

The findings, published online today in Nature Communications, show that causes genetic rearrangements in DNA that result in meningiomas, say co-principal investigators Gelareh Zadeh, neurosurgeon-scientist, Head of Surgical Oncology, and Ken Aldape, neuropathologist-scientist, Director, MacFeeters-Hamilton Neuro-Oncology Research Program, Princess Margaret Cancer Centre, University Health Network.

Dr. Zadeh is an Associate Professor, Division of Neurosurgery, and holds the Wilkins Family Chair in Brain Tumor Research; and Dr. Aldape, Professor, Laboratory Medicine and Pathobiology, both at University of Toronto.

The study compared and contrasted the biology of radiation-induced meningiomas (RIMs) to those that appear sporadically in the general population. "Radiation-induced meningiomas appear the same on MRI and pathology, feel the same during surgery and look the same under the operating microscope. What's different is they are more aggressive, tend to recur in multiples and invade the brain, causing significant morbidity and limitations (or impairments) for individuals who survive following childhood radiation," says Dr. Zadeh.

The video will load shortly.
Neuroscientists have uncovered the genetic basis for why many long-term survivors of childhood cancer develop meningiomas, the most common adult brain tumor, decades after their treatment with cranial radiation. Credit: UHN

The research team analyzed RIMs from patients who had received cranial-spinal radiation as children; the majority of whom (74%) had survived either leukemia or pediatric brain . The study also showed that RIMs developed regardless of the radiation dose by collaborating with scientists in Germany where low-dose radiation was a common treatment many years ago for scalp ringworm.

"By understanding the biology, the goal is to identify a therapeutic strategy that could be implemented early on after childhood radiation to prevent the formation of these tumours in the first place," says Dr. Zadeh.

Dr. Aldape says: "It is an important clinical problem because it presents a paradoxical dilemma that while cranial-spinal radiation is needed to cure many cancers, an unfortunate consequence is that 10-to-15-years following radiation treatment some survivors develop meningiomas.

"Our research identified a specific rearrangement involving the NF2 gene that causes radiation-induced meningiomas. But there are likely other that are occurring as a result of that radiation-induced DNA damage. So one of the next steps is to identify what the radiation is doing to the DNA of the meninges."

He adds: "In addition, identifying the subset of patients who are at highest risk to develop is critical so that they could be followed closely for early detection and management."

Explore further: Risk of subsequent malignancies reduced among childhood cancer survivors

Related Stories

Risk of subsequent malignancies reduced among childhood cancer survivors

February 28, 2017
Although the risk of subsequent malignancies for survivors of childhood cancer diagnosed in the 1990s remains increased, the risk is lower compared with those diagnosed in the 1970s, a decrease that is associated with a reduction ...

Radiation a risk factor for brain tumors in young people, study finds

November 3, 2014
In people under age 30, radiation is a risk factor for a type of brain tumor called a meningioma, a Loyola University Medical Center study has found.

As radiation therapy declined so did second cancers in childhood cancer survivors

February 28, 2017
Childhood cancer survivors are living longer. Now research shows they are also less likely to develop second cancers while still young. The decline followed a sharp drop in the use of radiation therapy for treatment of childhood ...

Team maps genomic landscape of schwannoma tumours

October 11, 2016
Researchers from the University Health Network (UHN); Toronto Western Neurosurgery Division and MacFeeters Hamilton Neuro-oncology Program at the Princess Margaret Cancer Centre have described the genomic landscape of schwannomas ...

ASCO: single radiation Tx enough for spinal pain in cancer mets

June 5, 2017
(HealthDay)—Just one dose of radiation works as well as a full week of treatment for metastatic spinal canal compression, according to a study presented at the annual meeting of the American Society of Clinical Oncology, ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.